Inari Medical price target lowered to $46 from $55 at Truist

Truist lowered the firm’s price target on Inari Medical to $46 from $55 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results for the MedTech sector. While the firm believes that any hurricane related headwind call-outs for Q4 will generally get “a pass” from investors, it could cause companies with elective or deferrable procedure areas to see more muted guide increases, the analyst tells investors in a research note. For the stock, Truist contends that the SMID group has experienced some multiple compression, but it also believes that there could be a path for the multiple re-rate back into the SMID high growth peer level.